UK Innovation Map
Compare placesDifferent, not ranked.
Two or three clusters, read side by side across sectors, research, companies, capital, infrastructure, government designations and UKIZ relevance. There is no score and no ranking: British clusters are different from one another, not better or worse than one another.
Choose up to three clusters
- London
- Cambridge
- Oxford
- Manchester
- Birmingham & the West Midlands
- Bristol & Bath
- Sheffield & Rotherham
- Leeds & West Yorkshire
- Liverpool City Region
- Newcastle & the North East
- Teesside & the Humber
- Edinburgh
- Glasgow & the Central Belt
- Belfast
- Cardiff & South Wales
- Southampton & Portsmouth
- Cornwall & Plymouth
- Nottingham & Derby
- Norwich & the East
Side by side
| Dimension | Leeds & West YorkshireYorkshire and the Humber | CambridgeEast of England | Bristol & BathSouth West |
|---|---|---|---|
| Sectors | Life Sciences, Digital Technologies, Financial Technology Supporting: Artificial Intelligence, Advanced Manufacturing, Creative Industries | Life Sciences, Semiconductors, Engineering Biology, Artificial Intelligence Supporting: Quantum Technologies, Advanced Materials, AgriTech & FoodTech, Digital Technologies | Semiconductors, Robotics & Autonomous Systems, Quantum Technologies, Defence & Security Supporting: Creative Industries, Advanced Manufacturing, Artificial Intelligence, Clean Energy |
| Research |
|
|
|
| Companies |
|
|
|
| Infrastructure | Not recorded on the map. Health data infrastructure, teaching hospitals and university research facilities. |
University and institute laboratories, genomics and biomedical campus facilities, and semiconductor design capability. |
Quantum and robotics laboratories, national composites facilities and aerospace test capability. |
| Capital | Financial services depth locally, but early-stage health technology capital remains limited. | Specialist deep tech and life science funds, university-linked funds, and corporate partners; strong at seed, thinner at growth stage relative to demand. | An established angel and seed base with strong deep tech interest; growth rounds usually come from London or the US. |
| Government programmes | No place-based designation recorded. | No place-based designation recorded. | No place-based designation recorded. |
| What exists | National health data organisations, medical technology, a large financial and professional services base and a research university with data and materials strength. | Extreme research density for its size: life sciences and genomics, semiconductor and processor IP, engineering biology and AI, with a mature spin-out culture and specialist investors who understand long timelines. | Semiconductor and processor design, quantum engineering, robotics and autonomous systems, aerospace and composites, and a creative and screen economy of national significance. |
| What's missing · UKIZ interpretation | A clear route for companies to work with health data at scale, and clinical adoption pathways that move faster than pilot projects. | Ownership retention. Discovery and early company formation work; the Series B onward stage frequently transfers ownership overseas. Laboratory and scale-up space, power and housing also constrain growth. | Fabrication and volume production capacity to match the design strength, and hardware-friendly capital. Companies scale by moving production abroad. |
| What could connect · UKIZ interpretation | Leeds health data capability connected to Manchester clinical research and to medical technology manufacturing, giving companies discovery, evidence and production in one region. | Cambridge discovery connected to UK manufacturing and biomanufacturing capacity, and to later-stage domestic capital, so that value created here is realised here rather than acquired out of the country. | Bristol design capability connected to South Wales compound semiconductor fabrication and to composites and aerospace manufacturing, a western technology corridor with a complete chain. |
| UKIZ relevance | Health data at population scale is a national asset. The proposed Manchester mission and Leeds capability are complementary rather than competing. | Cambridge produces intellectual property at a rate few places match, and loses ownership of too much of it at Series B. The proposed Oxford-Cambridge zone concentrates on commercialisation and retention rather than on more discovery. | Bristol's design and robotics capability has historically been acquired rather than scaled. The relevant missions concentrate on the capital and customer connections that let companies stay independent. |
| Last verified | 15 August 2026 | 15 August 2026 | 15 August 2026 |
Proposed by UKIZ · independent · not a government designation